1/9
08:43 am
abvx
Abivax (NASDAQ:ABVX) had its price target raised by analysts at Morgan Stanley from $101.00 to $145.00. They now have an "overweight" rating on the stock.
Low
Report
Abivax (NASDAQ:ABVX) had its price target raised by analysts at Morgan Stanley from $101.00 to $145.00. They now have an "overweight" rating on the stock.
1/8
08:42 am
abvx
Abivax (NASDAQ:ABVX) was given a new $131.00 price target on by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Abivax (NASDAQ:ABVX) was given a new $131.00 price target on by analysts at Oppenheimer Holdings, Inc..
1/8
08:02 am
abvx
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
1/8
07:17 am
abvx
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Medium
Report
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at BTIG Research.
1/7
04:05 pm
abvx
Abivax Provides 2026 Corporate Outlook
Medium
Report
Abivax Provides 2026 Corporate Outlook
12/22
07:42 pm
abvx
Why Abivax Stock Was on Fire Today [Yahoo! Finance]
Low
Report
Why Abivax Stock Was on Fire Today [Yahoo! Finance]
12/18
04:05 pm
abvx
Abivax to be Added to Nasdaq Biotechnology Index
Low
Report
Abivax to be Added to Nasdaq Biotechnology Index
12/18
09:03 am
abvx
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/17
04:05 pm
abvx
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Low
Report
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
12/16
04:06 pm
abvx
Abivax (NASDAQ:ABVX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Abivax (NASDAQ:ABVX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/16
08:05 am
abvx
Abivax (NASDAQ:ABVX) had its price target raised by analysts at Citizens Jmp from $114.00 to $131.00. They now have a "market outperform" rating on the stock.
Low
Report
Abivax (NASDAQ:ABVX) had its price target raised by analysts at Citizens Jmp from $114.00 to $131.00. They now have a "market outperform" rating on the stock.
12/16
07:09 am
abvx
Abivax (NASDAQ:ABVX) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Abivax (NASDAQ:ABVX) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/15
04:07 pm
abvx
Abivax Presents Third Quarter 2025 Financial Results
Medium
Report
Abivax Presents Third Quarter 2025 Financial Results
12/13
01:10 am
abvx
Medium
Report
11/24
09:04 am
abvx
Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
abvx
Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/7
06:19 am
abvx
Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/5
07:02 pm
abvx
Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
11/4
07:21 am
abvx
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/3
04:05 pm
abvx
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
Low
Report
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis